- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01577914
Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Carvedilol Tablets USP 12.5 mg With Coreg® 12.5 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective of this pivotal study was to assess the bioequivalence between Test Product: Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Coreg® (Carvedilol Tablets) 12.5 mg Tablets of M/s GlaxoSmithKline, under fasting condition in normal, healthy, adult, human subjects in a randomized crossover study.
The study was conducted with 42 healthy adult subjects. In each study period, a single 12.5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.
The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Gujarat
-
Ahmedabad, Gujarat, India
- Accutest Research Lab (I) Pvt. Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female human subjects, age in the range of 18 - 45 years.
- Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.
- Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).
- Subjects with clinically acceptable findings as determined by haemogram, biochemistry, serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray (chest X-ray if required).
- Willingness to follow the protocol requirements as evidenced by written informed consent.
- Confirming and agreeing to, not using any prescription and over the counter medications including vitamins and minerals for 14 days prior to study and during the course of the study.
- No history of drug abuse in the past one year.
- Non-smokers and non-alcoholics.
- For female subject is child bearing potential practicing acceptable method of birth control for the duration of the study as judged by Investigator such as Condom, Foams, Jellies,Diaphragm, Intrauterine device and Abstinence.
OR
- is surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject).
Exclusion Criteria:
- Known history of hypersensitivity to Carvedilol, 4-hydroxyphenyl-carvedilol or related drugs.
- Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.
- Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
- History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases and bleeding tendency.
- Participation in a clinical drug study or bioequivalence study within 90 days prior to present study.
- History of malignancy or other serious diseases.
- Refusal to abstain from food for at least ten (10) hours prior to study drug administration and for at least four (04) hours post-dose, in each study period.
- Any contraindication to blood sampling or difficulty in accessibility of veins.
- Refusal to abstain from fluid for at least 01.00 hour prior to study drug administration and for at least 01.00 additional hour post-dose, in each study period except about 240 mL of water given during administration of study drug.
- Refusal to avoid the use of xanthine-containing food or beverages (chocolates,tea, coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for 48.00 hours prior to dosing until the last blood sample collection of last study period.
- Blood donation within 90 days prior to the commencement of the study.
- Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.
- Found positive in breath alcohol test done before check-in for each study period.
- Found positive in urine test for drugs of abuse done before check-in for each study period.
- Refusal to abstain from consumption of tobacco products 24 hours prior to dosing until the last blood sample collection of last study period.
- History of problem in swallowing Tablets.
- Female subject, demonstrating positive urine pregnancy test at the time of screening.
- Female subject, demonstrating positive Serum (ß) Beta- hCG (Human Chorionic Gonadotropin) test before check-in for each study period.
- Female subject, currently breast feeding or lactating.
- Female subjects not willing to use acceptable method of contraception from the date of screening until the completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Carvedilol Tablets USP 12.5 mg
Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
|
12.5mg tablet once a day
Other Names:
|
ACTIVE_COMPARATOR: Coreg®
Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
|
12.5mg tablet once a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioequivalence is based on Cmax and AUC parameters.Sampling Hours: Pre-dose and at 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.50, 03.00, 04.00, 05.00, 06.00, 08.00, 09.00, 10.00, 12.00, 16.00, 20.00, 24.00, 36.00 and 48.00 hours post-dose.
Time Frame: 5 months
|
Bioequivalence was concluded if: The 90% confidence interval of geometric mean ratio of Cmax, AUC0-t and AUC0-inf between test and reference product fall within the range of 80.00 % to 125.00 % for Carvedilol. |
5 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Protective Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Antioxidants
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Carvedilol
Other Study ID Numbers
- Ipca/ARL/203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fasting State
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
CerbaXpertRecruitingEvaluate the Physiological Stability of NIS4 Biomarker Between the Fed and Fasting State in Patients With the Target Condition (NAFLD)France
-
Pusan National University Yangsan HospitalCompletedImpaired Fasting GlucoseKorea, Republic of
-
The University of Hong KongChinese University of Hong KongCompletedProgression From Impaired Fasting Glucose to Diabetes MellitusHong Kong
-
VA Office of Research and DevelopmentUniversity of CincinnatiTerminatedDiabetes Mellitus | Prediabetes | Impaired Fasting GlucoseUnited States
-
YangjinPeking University Third HospitalNot yet recruitingPrediabetic State | Impaired Glucose Tolerance | Impaired Fasting GlucoseChina
Clinical Trials on Carvedilol Tablets USP 12.5 mg
-
Mylan Pharmaceuticals IncCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Actavis Inc.Completed
-
Actavis Inc.Completed
-
Novartis PharmaceuticalsCompleted
-
NYU Langone HealthCompleted
-
Idorsia Pharmaceuticals Ltd.Janssen Biotech, Inc.CompletedResistant HypertensionSpain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
-
Ranbaxy Laboratories LimitedCompleted
-
Ranbaxy Laboratories LimitedCompleted
-
Edgewise Therapeutics, Inc.Medpace, Inc.; SYSNAV; ImagingNMDRecruitingBecker Muscular DystrophyUnited States, Netherlands, United Kingdom